Unity Biotechnology, Inc. (UBX)
NASDAQ: UBX · Real-Time Price · USD
0.6880
-0.0344 (-4.76%)
At close: Jun 5, 2025, 4:00 PM
0.7224
+0.0344 (5.00%)
After-hours: Jun 5, 2025, 4:09 PM EDT
Unity Biotechnology Stock Forecast
UBX's stock price has decreased by -55.99% in the past year and price targets may not have had time to catch up.
Stock Price Forecast
According to 3 professional analysts, the 12-month price target for Unity Biotechnology stock ranges from a low of $2.00 to a high of $8.00. The average analyst price target of $4.67 forecasts a 578.78% increase in the stock price over the next year.
Price Target: $4.67 (+578.78%)
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Unity Biotechnology stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Dec '24 | Jan '25 | Feb '25 | Mar '25 | Apr '25 | May '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 2 | 2 | 2 | 3 | 3 | 2 |
| Buy | 1 | 0 | 0 | 0 | 0 | 0 |
| Hold | 0 | 0 | 0 | 0 | 0 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 3 | 2 | 2 | 3 | 3 | 3 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy → Hold Downgrades $4 → $2 | Strong Buy → Hold | Downgrades | $4 → $2 | +190.70% | May 27, 2025 |
| Chardan Capital | Chardan Capital | Strong Buy Maintains $4 | Strong Buy | Maintains | $4 | +481.40% | Apr 23, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $4 | Strong Buy | Reiterates | $4 | +481.40% | Apr 23, 2025 |
| Chardan Capital | Chardan Capital | Strong Buy Maintains $6 → $4 | Strong Buy | Maintains | $6 → $4 | +481.40% | Mar 25, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $8 → $4 | Strong Buy | Maintains | $8 → $4 | +481.40% | Mar 25, 2025 |
Financial Forecast
Revenue This Year
n/a
Revenue Next Year
15.02M
EPS This Year
-1.27
from -1.54
EPS Next Year
-0.76
from -1.27
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | n/a | 26.0M | 62.6M | ||
| Avg | n/a | 15.0M | 51.2M | ||
| Low | n/a | n/a | 40.9M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | 316.6% | ||
| Avg | - | - | 240.7% | ||
| Low | - | - | 172.4% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -0.82 | -0.58 | -0.01 | ||
| Avg | -1.27 | -0.76 | -0.55 | ||
| Low | -1.60 | -0.98 | -1.05 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | - | ||
| Avg | - | - | - | ||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.